Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)

Epilepsia

Volumn 58, Issue 2, 2017, Pages 181-221

  Bialer, Meir ^a   Johannessen, Svein I ^b,c   Levy, René H ^d   Perucca, Emilio ^e,f   Tomson, Torbjörn ^g   White, H Steve ^d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b National Center for Epilepsy   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

^f C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiepileptic drugs; Drug development; Epilepsy; Epilepsy targets

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ADENOSINE; ANTICONVULSIVE AGENT; BRIVARACETAM; BUMETANIDE; CANNABIDIOL; CANNABIDIVARIN; DEOXYGLUCOSE; EVEROLIMUS; FENFLURAMINE; FV 082; GANAXOLONE; HUPERZINE A; IOP 2198; MINOCYCLINE; NAX 810 2; SAGE 217; SAGE 689; UNCLASSIFIED DRUG; VALNOCTAMIDE; NEW DRUG;

ADVERSE DRUG REACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; HUMAN; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; ORGANIZATION; RESEARCH;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; RESEARCH REPORT;

EID: 85010549236     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13634     Document Type: Review

References (189)

1. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89–124.
2. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013;103:2–30.
3. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015;111:85–141.
4. Boison D. Adenosinergic signaling in epilepsy. Neuropharmacology 2016;104:131–139.
5. Williams-Karnesky RL, Sandau US, Lusardi TA, et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest 2013;123:3552–3563.
6. Boison D, Singer P, Shen HY, et al. Adenosine hypothesis of schizophrenia – opportunities for pharmacotherapy. Neuropharmacology 2012;62:1527–1543.
7. Boison D. Adenosine augmentation therapy for epilepsy. In Noebels JL, Avoli M, Rogawski MA, et al. (Eds) Jasper's basic mechanisms of the epilepsies. 4th Ed. Oxford: Oxford University Press, 2012:1150–1160.
8. Boison D, Huber A, Padrun V, et al. Seizure suppression by adenosine-releasing cells is independent of seizure frequency. Epilepsia 2002;43:788–796.
9. Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 2013;65:906–943.
10. Li T, Ren G, Lusardi T, et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest 2008;118:571–582.
11. Aronica E, Zurolo E, Iyer A, et al. Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy. Epilepsia 2011;52:1645–1655.
12. Reddy DS, Rogawski MA. Neurosteroids – endogenous regulators of seizure susceptibility and role in the treatment of epilepsy. In Noebels JL, Avoli M, Rogawski MA, et al. (Eds) Jasper's basic mechanisms of the epilepsies. 4th Ed. Oxford: Oxford University Press, 2012:984–1002.
13. Rogawski MA, Loya CM, Reddy K, et al. Neuroactive steroids for the treatment of status epilepticus. Epilepsia 2013;54:93–98.
14. Belelli D, Casula A, Ling A, et al. The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology 2002;43:651–661.
15. Timby E, Balgard M, Nyberg S, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology 2006;186:414–424.
16. van Broekhoven F, Backstrom T, van Luijtelaar G, et al. Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. Psychoneuroendocrinology 2007;32:555–564.
17. Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 2016;57:538–548.
18. Klitgaard H, Matagne A, Lamberty Y. Use of epileptic animals for adverse effect testing. Epilepsy Res 2002;50:55–65.
19. Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154:1662–1671.
20. Leclercq K, Kaminski RM. Anticonvulsant effects of brivaracetam in the 6 Hz fully-kindled mice. Epilepsia 2015;56(Suppl. 1):53. Abstract.
21. Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2016;57:201–209.
22. Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 2011;664:36–44.
23. Wood M, Urbain D, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the SV2A protein. Epilepsia 2015;56(Suppl. 1):215. Abstract.
24. Yang X, Bognar J Jr, He T, et al. Brivaracetam augments short-term depression and slows vesicle recycling. Epilepsia 2015;56:1899–1909.
25. Niespodziany I, Andre VM, Leclere N, et al. Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons. CNS Neurosci Ther 2015;21:241–251.
26. Niespodziany I, Lukyanetz EA, Matagne A, et al. Brivaracetam does not modulate the major ionic conductances in neurons. Epilepsia 2015;56(Suppl. 1):192–193. Abstract.
27. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1–43.
28. D'Souza J, Perucca E. Brivaracetam. In Shorvon SD, Perucca E, Engel J Jr (Eds) The treatment of epilepsy. 4th Ed. Oxford: Wiley-Blackwell, 2016:418–430.
29. Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos 2016;44:792–799.
30. Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol 2016;56:1591–1602.
31. Chanteux H, Kervyn S, Gerin B, et al. In vitro pharmacokinetic profile of brivaracetam reveals low risk of drug-drug interaction and unrestricted brain permeability. Epilepsy Curr 2015;15(Suppl. 1):333. Abstract.
32. Otoul C, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures, 2015. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2311821. Accessed September 19, 2016.
33. Stockis A, Sargentini-Maier ML, Brodie M. Brivaracetam and carbamazepine interaction study in adult patients with epilepsy. Epilepsia 2015;56(Suppl. 1):210–211. Abstract.
34. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 2008;49:1239–1276.
35. McDonough B, Colson A, Stockis A, et al. Brivaracetam-induced elevation of carbamazepine-epoxide levels: a safety analysis, 2015. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2326297. Accessed September 19, 2016.
36. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015;56:1890–1898.
37. Quarato PP, Whitesides J, Johnson ME, et al. Efficacy and safety of adjunctive brivaracetam for partial-onset (focal) seizures: pooled results from three fixed-dose, randomised, double-blind, placebo-controlled Phase III studies. Epilepsia 2015;56(Suppl. 1):208–209. Abstract.
38. Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:47–56.
39. Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55:57–66.
40. UCB. Briviact – summary of product characteristics, 2016. Available at:https://www.medicines.org.uk/emc/medicine/31452. Accessed June 9, 2016.
41. Chung S, Klein P, Sperling M, et al. Efficacy of brivaracetam as adjunctive therapy in partial-onset (focal) seizures among patients with prior levetiracetam, carbamazepine, lamotrigine or topiramate exposure. Neurology 2016;86(Suppl. 16):P2.027.
42. Diaz A, Elmoufti S, Schiemann J, et al. Efficacy and safety of adjunctive brivaracetam (BRV) for partial-onset (focal) seizures (POS) in patients with Type IC seizures at baseline: pooled results from three fixed-dose, randomized, double-blind, placebo-controlled, phase III studies. Neurology 2016;86(Suppl. 16):P2.042.
43. Klein P, Johnson M, Schiemann J, et al. Post hoc analysis of time to sustained 50% responder status in three Phase III studies of brivaracetam as adjunctive treatment for partial-onset (focal) seizures (POS). Neurology 2016;86(Suppl. 16):P2.036.
44. Klein P, Quarato P, Mameniškiene R, et al. Efficacy and safety of adjunctive brivaracetam for partial-onset (focal) seizures overall and in elderly patients: a pooled analysis from three phase 3 studies, 2015. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2327320. Accessed September 19, 2016.
45. Johnson M, Toledo M, Kwan P, et al. Efficacy of long-term adjunctive brivaracetam treatment for partial-onset seizures, 2015. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2327641. Accessed September 19, 2016.
46. Ben-Menachem E, Mameniškien≐ R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in three pooled clinical studies. Neurology 2016;87:314–323.
47. Toledo M, Johnson ME, Whitesides J, et al. Safety and tolerability of long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia 2015;56(Suppl. 1):213. Abstract.
48. Elmoufti S, Whitesides J, Borghs S. Time from first exposure to discontinuation due to adverse events or lack of efficacy in the brivaracetam clinical program, 2015. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2322836. Accessed September 19, 2016.
49. Ward A, Heel RC. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;28:426–464.
50. Alvarez-Leefmans F. Intracellular chloride regulation. In Sperelakis N (Ed) Cell physiology sourcebook. Essentials of membrane biophysics. 4th Ed. London: Academic Press, 2012:221–259.
51. Kaila K, Price TJ, Payne JA, et al. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci 2014;15:637–654.
52. Löscher W, Puskarjov M, Kaila K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 2013;69:62–74.
53. Pressler RM, Boylan GB, Marlow N, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol 2015;14:469–477.
54. Feit PW. Bumetanide–the way to its chemical structure. J Clin Pharmacol 1981;21:531–536.
55. Töllner K, Brandt C, Romermann K, et al. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. Eur J Pharmacol 2015;746:167–173.
56. Töllner K, Brandt C, Topfer M, et al. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol 2014;75:550–562.
57. Töpfer M, Töllner K, Brandt C, et al. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy. Eur J Neurosci 2014;39:673–687.
58. Puskarjov M, Kahle KT, Ruusuvuori E, et al. Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures. Epilepsia 2014;55:806–818.
59. Erker T, Brandt C, Töllner K, et al. The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice. Epilepsia 2016;57:698–705.
60. Lykke K, Töllner K, Römermann K, et al. Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter. Br J Pharmacol 2015;172:4469–4480.
61. − cotransport splice variants in human tissues using kinetic polymerase chain reaction. Anal Biochem 2001;298:218–230.
62. Morita Y, Callicott JH, Testa LR, et al. Characteristics of the cation cotransporter NKCC1 in human brain: alternate transcripts, expression in development, and potential relationships to brain function and schizophrenia. J Neurosci 2014;34:4929–4940.
63. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791–802.
64. Gloss D, Vickrey B. Cannabinoids in epilepsy. Cochrane Database Syst Rev 2014. Available at:http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009270.pub3/full. Accessed March 5, 2016.
65. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332:569–577.
66. Ibeas Bih C, Chen T, Nunn AV, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 2015;12:699–730.
67. Hill AJ, Hill TD, Whalley BJ. The development of cannabinoid based therapies for epilepsy. In Murillo-Rodriguez E (Ed) Endocannabinoids: molecular, pharmacological, behavioural and clinical features. Sharjah, United Arab Emirates, Bentham Science Publishers, 2013:164–204.
68. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsive effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344–352.
69. Hill AJ, Jones NA, Smith I, et al. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci Lett 2014;566:269–274.
70. Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. London: Pharmaceutical Press; 2004.
71. Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015;56:1246–1251.
72. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270–278.
73. Devinsky O, Thiele E, Laux L, et al. Efficacy and safety of Epidioloex (cannabidiol) in children and young adults with treament-resistant epilepsy: Update from the expanded access program, 2015. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2414222. Accessed May 19, 2016.
74. GW Pharmaceuticals. GW Pharmaceuticals announces positive Phase 3 pivotal study results for Epidiolex, 2016: Press Relase. Available at:http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Study%20Results%20for%20Epidiolex%20cannabidiol.aspx. Accessed June 6, 2016.
75. GW Pharmaceuticals. GW Pharmaceuticals announces positive Phase 3 pivotal study results for Epidiolex (cannabidiol) in the treatment of Lennox-Gastat syndrome, 2016: Press Release. Available at:http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Trial%20Results%20for%20Epidiolex%20cannabidiol%20in%20the%20Treatment%20of%20Lennox-Gastaut%20Syndrome.aspx. Accessed August 12, 2016.
76. Hill AJ, Mercier MS, Hill TD, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 2012;167:1629–1642.
77. Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 2013;170:679–692.
78. Amada N, Yamasaki Y, Williams CM, et al. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ 2013;1:e214.
79. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479–1494.
80. De Petrocellis L, Orlando P, Moriello AS, et al. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 2012;204:255–266.
81. Pan Y, Sutula T, Rutuecki P. Evidence for use-dependent and presynaptic actions of 2DG on abnormal synaptic network activity in the CA3 region of the hippocampus, 2014. Society for Neuroscience Annual Meeting. Abstract. Available at:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=fc200e06-75fe-41ff-b0e6-f75b08b3c536&cKey=aef8f5bb-1d48-410d-88e9-1abf0f5d489f&mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7. Accessed September 19, 2016.
82. Stafstrom CE, Ockuly JC, Murphree L, et al. Anticonvulsant and antiepileptic actions of 2-deoxy-d-glucose in epilepsy models. Ann Neurol 2009;65:435–447.
83. Lian XY, Khan FA, Stringer JL. Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J Neurosci 2007;27:12007–12011.
84. Garriga-Canut M, Schoenike B, Qazi R, et al. 2-Deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 2006;9:1382–1387.
85. Sutula T, Franzoso S. Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration AFTER seizures, 2008. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/find/franzoso%20sutula%20/2/7/0. Accessed September 19, 2016.
86. Hutchinson E, Elangbam N, Hurley S, et al. Quantitative manganese-enhanced MRI detection of differences between kindling-susceptible and kindling-resistant strains of rats, 2012. Society for Neuroscience Annual Meeting. Abstract. Available at:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e1da28a6-5cdd-4715-8f8d-aa4e37f7c1d9&cKey=f2a78cb8-ebc6-407a-80a2-1073dc8048ba&mKey=70007181-01c9-4de9-a0a2-eebfa14cd9f1. Accessed on September 19, 2016.
87. Hutchinson E, Dettman K, Ruteki P, et al. MRI and DTI markers for TBI-related brain tissue damage and plasticity in a rat CCI model demonstrate protective effects of 2DG, 2010. Society for Neuroscience Annual Meeting. Abstract. Available at:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8fa36832-b91c-44a8-aa3b-51ca0cd5bca2&cKey=e1f8ea44-e197-43dc-9e20-7a65c0ecc87c&mKey=e5d5c83f-ce2d-4d71-9dd6-fc7231e090fb. Accessed September 19, 2016.
88. Langberg T, Dashek R, Mulvey B, et al. Distinct behavioral phenotypes in novel “fast” kindling-susceptible and “slow” kindling-resistant rat strains selected by stimulation of the hippocampal perforant path. Neurobiol Dis 2016;85:122–129.
89. Langberg T, Miller K, Stafstrom CE, et al. Unique strains of kindling-susceptible and kindling-resistant rats are behaviorally distinct: evidence background on both seizure-induced plasticity and behavior, 2012. Society for Neuroscience Annual Meeting. Abstract. Available at:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=cd8ca5ab-69d5-4a36-bbfb-c3a51411bfc6&cKey=e531a15a-1f01-45f7-829c-947da63495a7&mKey=70007181-01c9-4de9-a0a2-eebfa14cd9f1. Accessed September 19, 2016.
90. Rutecki P, Osting S, Langberg T, et al. Therapeutic effects of 2DG at the time of injury on fear conditioning and fear context recall at long intervals after TBI in plasticity-susceptible rats, 2013. Society for Neuroscience Annual Meeting. Abstract. Available at:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=efe712b4-5037-4ebc-9284-720ea76882aa&cKey=3239c62b-f49f-4252-9579-79304dbda07e&mKey=8d2a5bec-4825-4cd6-9439-b42bb151d1cf. Accessed September 19, 2016.
91. Cech C, Hanson M, Ting L, et al. Subtle seizures after TBI in a unique strain of kindling-susceptible rats: electrographic, behavioral, and phenotypic features, 2012. American Epilepsy Society Annual Meeting. Abstract. Available at:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/15981. Accessed September 19, 2016.
92. Elman I, Sokoloff L, Adler CM, et al. The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers. Brain Res 1999;815:243–249.
93. Gasior M, Yankura J, Hartman AL, et al. Anticonvulsant and proconvulsant actions of 2-deoxy-d-glucose. Epilepsia 2010;51:1385–1394.
94. Minor RK, Smith DL Jr, Sossong AM, et al. Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol 2010;243:332–339.
95. Terse PS, Joshi PS, Bordelon NR, et al. 2-Deoxy-d-glucose (2-DG)-induced cardiac toxicity in rat: NT-proBNP and BNP as potential early cardiac safety biomarkers. Int J Toxicol 2016;35:284–293.
96. Ockuly JC, Gielissen JM, Levenick CV, et al. Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats. Epilepsy Res 2012;101:246–252.
97. Stein M, Lin H, Jeyamohan C, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010;70:1388–1394.
98. Raez LE, Langmuir V, Tolba K, et al. Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas. ASCO Ann. Meeting Proc. J Clin Oncol 2007;25(Suppl. 18):14025. Abstract.
99. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005;181:507–514.
100. Curatolo P, Moavero R. mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol 2012;10:404–415.
101. Crino PB. Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found Symp 2007;288:260–272; discussion 272–281.
102. Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev Neurother 2013;13:627–638.
103. Galanopoulou AS, Gorter JA, Cepeda C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 2012;53:1119–1130.
104. Tavazoie SF, Alvarez VA, Ridenour DA, et al. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 2005;8:1727–1734.
105. Zeng LH, Xu L, Gutmann DH, et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008;63:444–453.
106. Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008;28:5422–5432.
107. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009;29:6964–6972.
108. Huang X, Zhang H, Yang J, et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 2010;40:193–199.
109. Erlich S, Alexandrovich A, Shohami E, et al. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 2007;26:86–93.
110. Park J, Zhang J, Qiu J, et al. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab 2012;32:330–340.
111. Sankar R, Auvin S, Kwon YS, et al. Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia 2010;51(Suppl. 3):39–42.
112. Talos DM, Sun H, Jackson M, et al. Rapamycin attenuates the increases in seizure susceptibility and neuronal excitability following neonatal seizures in rat. Epilepsy Curr 2011;11(Suppl. 1):A08. Abstract.
113. Russo E, Citraro R, Donato G, et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013;69:25–36.
114. + channel is modulated by FK506 and rapamycin. Brain Res 1998;786:255–258.
115. Raab-Graham KF, Haddick PC, Jan YN, et al. Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 2006;314:144–148.
116. Wang Y, Barbaro MF, Baraban SC. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett 2006;401:35–39.
117. Buckmaster PS, Ingram EA, Wen X. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci 2009;29:8259–8269.
118. Dello Russo C, Lisi L, Tringali G, et al. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol 2009;78:1242–1251.
119. Wong M. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Exp Neurol 2013;244:22–26.
120. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83–95.
121. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125–132.
122. Shipkova M, Hesselink DA, Holt DW, et al. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit 2016;38:143–169.
123. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801–1811.
124. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013;74:679–687.
125. Wiegand G, May TW, Ostertag P, et al. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol 2013;17:631–638.
126. Cardamone M, Flanagan D, Mowat D, et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 2014;164:1195–1200.
127. French J, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for the treatment of refractory seizures associated with tuberous sclerosis complex: results from a randomized, placebo-controlled, phase 3 trial, 2016. American Academy of Neurology Annual Meeting. Abstract. Available at:http://www.abstractsonline.com/pp8/#!/4046/presentation/10295. Accessed September 19, 2016.
128. Jozwiak S, Kotulska K, Berkowitz N, et al. Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr 2016;172:151–155.e151.
129. Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 2015;52:281–289.
130. Bayat A, Hjalgrim H, Moller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia 2015;56:e36–e39.
131. Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav 2015;44:104–109.
132. Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav 1988;30:715–721.
133. Zhang Y, Kecskes A, Copmans D, et al. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine. PLoS ONE 2015;10:e0125898.
134. Sourbron J, Schneider H, Kecskes A, et al. Serotonergic modulation as effective treatment for Dravet syndrome in a zebrafish mutant model. ACS Chem Neurosci 2016;7:588–598.
135. Gilbert DL, Franko BV, Ward JW, et al. Toxicologic studies of fenfluramine. Toxicol Appl Pharmacol 1971;19:705–711.
136. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581–588.
137. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609–616.
138. Caccia S, Ballabio M, De Ponte P. Pharmacokinetics of fenfluramine enantiomers in man. Eur J Drug Metab Pharmacokinet 1979;4:129–132.
139. Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord 2015;8:328–338.
140. Boel M, Casaer P. Add-on therapy of fenfluramine in intractable self-induced epilepsy. Neuropediatrics 1996;27:171–173.
141. Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012;53:1131–1139.
142. Ceulemans B, Schoonjans AS, Marchau F, et al. Five-year extended follow-up of 10 Dravet patients treated with fenfluramine. Epilepsia 2016;57:e129–e134.
143. Schoonjans AS, Paelinck B, Marchau F, et al. Low-dose add-on fenfluramine in Dravet syndrome: effect on seizure control, sleep quality, and quality of life in a prospective open-label study, 2016. International Child Neurology Congress. Abstract. Available at:http://icnc2016.org/wp-content/uploads/2016/04/Complete-platform-abstract-book.pdf. Accessed September 20, 2016.
144. Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061–1066.
145. Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 1997;280:1284–1295.
146. Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neurosci Lett 2010;470:6–9.
147. Yu D, Thakor DK, Han I, et al. Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. Proc Natl Acad Sci U S A 2013;110:E746–E755.
148. Tang XC, Han YF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev 2009;5:281–300.
149. Gersner R, Ekstein D, Dhamne SC, et al. Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition. Epilepsy Res 2015;117:97–103.
150. Chu D, Liu W, Li Y, et al. Pharmacokinetics of huperzine A in dogs following single intravenous and oral administrations. Planta Med 2006;72:552–555.
151. Qian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin 1995;16:396–398.
152. Wang YE, Feng J, Lu WH, et al. Pharmacokinetics of huperzine A in rats and mice. Acta Pharmacol Sin 1988;9:193–196.
153. Li YX, Zhang RQ, Li CR, et al. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet 2007;32:183–187.
154. Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76:1389–1394.
155. Wang DD, Englot DJ, Garcia PA, et al. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav 2012;24:314–318.
156. Beheshti Nasr SM, Moghimi A, Mohammad-Zadeh M, et al. The effect of minocycline on seizures induced by amygdala kindling in rats. Seizure 2013;22:670–674.
157. Abraham J, Fox PD, Condello C, et al. Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures. Neurobiol Dis 2012;46:425–430.
158. Wang N, Mi X, Gao B, et al. Minocycline inhibits brain inflammation and attenuates spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neuroscience 2015;287:144–156.
159. Lang N, Rothkegel H, Terney D, et al. Minocycline exerts acute inhibitory effects on cerebral cortex excitability in humans. Epilepsy Res 2013;107:302–305.
160. Grieco JC, Ciarlone SL, Gieron-Korthals M, et al. An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurol 2014;14:232.
161. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10:91.
162. Robertson CR, Flynn SP, White HS, et al. Anticonvulsant neuropeptides as drug leads for neurological diseases. Nat Prod Rep 2011;28:741–762.
163. Robertson CR, Scholl EA, Pruess TH, et al. Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. J Med Chem 2010;53:1871–1875.
164. Mazarati A, Lu X, Kilk K, et al. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 2004;19:3235–3244.
165. Mazarati A, Lu X, Shinmei S, et al. Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 2004;128:431–441.
166. Mazarati A, Lu X. Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides 2005;39:277–280.
167. Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A 2002;99:7136–7141.
168. Lindskog S, Ahren B. Galanin: effects on basal and stimulated insulin and glucagon secretion in the mouse. Acta Physiol Scand 1987;129:305–309.
169. Lindskog S, Ahren B. Effects of galanin on insulin and glucagon secretion in the rat. Int J Pancreatol 1989;4:335–344.
170. Lindskog S, Dunning BE, Martensson H, et al. Galanin of the homologous species inhibits insulin secretion in the rat and in the pig. Acta Physiol Scand 1990;139:591–596.
171. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817–1824.
172. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555–1563.
173. Large CH, Sokal DM, Nehlig A, et al. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia 2012;53:425–436.
174. Roeloffs R, Wickenden AD, Crean C, et al. In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. J Pharmacol Exp Ther 2008;326:818–828.
175. Visser SA, Gladdines WW, van der Graaf PH, et al. Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo. J Pharmacol Exp Ther 2002;303:616–626.
176. Shekh-Ahmad T, Mawasi H, McDonough JH, et al. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav 2015;49:298–302.
177. Mawasi H, Shekh-Ahmad T, Finnell RH, et al. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide–Amide derivatives of valproic acid. Epilepsy Behav 2015;46:72–78.
178. Hen N, Shekh-Ahmad T, Yagen B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013;56:6467–6477.
179. Pouliot W, Bialer M, Hen N, et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013;231:145–156.
180. Shekh-Ahmad T, Hen N, Yagen B, et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014;55:353–361.
181. Wlodarczyk BJ, Ogle K, Lin LY, et al. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord 2015;17:615–625.
182. Bar-Klein G, Swissa E, Kamintsky L, et al. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia 2014;55:1953–1958.
183. Kaufmann D, West PJ, Smith MD, et al. sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Pharmacol Res 2016 Nov 24 [Epub ahead of print].
184. Kaufmann D, Bates EA, Yagen B, et al. sec-Butylpropylacetamide (SPD) has antimigraine properties. Cephalalgia 2016;36:924–935.
185. Spampanato J, Dudek FE. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia 2014;55:e94–e98.
186. Mawasi H, Bibi D, Shekh-Ahmad T, et al. Pharmacokinetic and pharmacodynamic analysis after various routes of administration of sec-butylpropylacetamide (SPD), a new CNS drug possessing a unique activity against status epilepticus. Mol Pharm 2016;13:2492–2496.
187. White HS, Alex AB, Pollock A, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012;53:134–146.
188. Tomson TBD, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honored drug. Lancet Neurol 2016;15:210–218.
189. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9:68–82.